In a preclinical model of ovarian cancer, an accelerated metastasis was observed together with hypoxia and VM after anti-angiogenic treatment with bevacizumab (an anti-VEGF-A monoclonal antibody) (9). This evidence concerns the gene VEGFA and ovarian cancer.